Subscribe to this column
Douglas W. Blayney, MD, FASCO
Douglas W. Blayney, MD, FASCO, is a medical oncologist and Professor at Stanford University School of Medicine. He is an ASCO Past President, and currently serves as a member of the CancerLinQ Physician Advisory Committee and the Cost of Cancer Task Force.
Dec 29, 2009
So... I've been thinking about how to use our existing data repositories for measuring cancer outcomes and for comparative effectiveness. QOPI is a great start (here)—it is oncologist-driven and adaptable; the...
Apr 22, 2009
Mortality and cost benefits of inpatient Health Information Technology—A cross sectional study from Texas hospitals
Another study, demonstrating the clinical utility of Clinical Information Technology (CIT)—including some positive influence on mortality and cost of care, albeit in non-oncology conditions, was published earlier this year.
Apr 11, 2009
A large, longitudinal study of EHR introduction in a not-for profit integrated health system shows a reduction in outpatient visits, an increase in virtual patient visits (either scheduled telephone visits or online through a patient portal), and maintenance of patient satisfaction.
Mar 12, 2009
Last week, I participated in a panel on cancer survivorship, chaired by melanoma survivor Sam Donaldson, formerly the White House correspondent of ABC News, at the NCCN conference in...
Feb 16, 2009
We initially put desktop computers into our exam rooms about three years ago. Like a lot of new tools, my colleagues and I have been variously...
Jan 23, 2009
Incentives for ePrescribingThe Wall Street Journal has a story last week on ePrescribing, written by Laura Landro, a WSJ managing editor and...